| Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 CJL Murray, T Vos, R Lozano, M Naghavi, AD Flaxman, C Michaud, ... The lancet 380 (9859), 2197-2223, 2012 | 11262 | 2012 |
| Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 T Vos, AD Flaxman, M Naghavi, R Lozano, C Michaud, M Ezzati, ... The lancet 380 (9859), 2163-2196, 2012 | 10178 | 2012 |
| Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic … MH Forouzanfar, A Afshin, LT Alexander, HR Anderson, ZA Bhutta, ... The lancet 388 (10053), 1659-1724, 2016 | 7877 | 2016 |
| Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic … T Vos, RM Barber, B Bell, A Bertozzi-Villa, S Biryukov, I Bolliger, ... The lancet 386 (9995), 743-800, 2015 | 7024 | 2015 |
| Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of … S Abdalla, F Abd-Allah, MI Abdel Aziz The Lancet, 2015 | 5470 | 2015 |
| The state of US health, 1990-2010: burden of diseases, injuries, and risk factors CJL Murray, J Abraham, MK Ali, M Alvarado, C Atkinson, LM Baddour, ... Jama 310 (6), 591-606, 2013 | 3194 | 2013 |
| Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying … CJL Murray, RM Barber, KJ Foreman, AA Ozgoren, F Abd-Allah, SF Abera, ... The Lancet 386 (10009), 2145-2191, 2015 | 2346* | 2015 |
| Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews PK Nelson, BM Mathers, B Cowie, H Hagan, D Des Jarlais, D Horyniak, ... The Lancet 378 (9791), 571-583, 2011 | 1612 | 2011 |
| Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965 BD Smith, RL Morgan, GA Beckett, Y Falck-Ytter, D Holtzman, CG Teo, ... Centers for Disease Control and Prevention 61 (RR-4), 1-32, 2012 | 1250 | 2012 |
| Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015 H Wang, TM Wolock, A Carter, G Nguyen, HH Kyu, E Gakidou, SI Hay, ... The lancet HIV 3 (8), e361-e387, 2016 | 773 | 2016 |
| Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990 … GBD 2013 Risk Factors Collaborators Lancet (London, England) 386 (10010), 2287, 2015 | 758 | 2015 |
| Sharing of drug preparation equipment as a risk factor for hepatitis C. H Hagan, H Thiede, NS Weiss, SG Hopkins, JS Duchin, ER Alexander American journal of public health 91 (1), 42, 2001 | 682 | 2001 |
| Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial DC Des Jarlais, D Paone, J Milliken, CF Turner, H Miller, J Gribble, Q Shi, ... The Lancet 353 (9165), 1657-1661, 1999 | 632 | 1999 |
| A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs H Hagan, ER Pouget, DC Des Jarlais Journal of Infectious Diseases 204 (1), 74-83, 2011 | 437 | 2011 |
| Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta‐analysis S Larney, H Kopinski, CG Beckwith, ND Zaller, DD Jarlais, H Hagan, ... Hepatology 58 (4), 1215-1224, 2013 | 384 | 2013 |
| Maintaining low HIV seroprevalence in populations of injecting drug users DC Des Jarlais, H Hagan, SR Friedman, P Friedmann, D Goldberg, ... Jama 274 (15), 1226-1231, 1995 | 367 | 1995 |
| Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs L Platt, S Minozzi, J Reed, P Vickerman, H Hagan, C French, A Jordan, ... Cochrane Database of Systematic Reviews, 2017 | 351 | 2017 |
| Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. H Hagan, DC Jarlais, SR Friedman, D Purchase, MJ Alter American Journal of Public Health 85 (11), 1531-1537, 1995 | 333 | 1995 |
| Syringe exchange and risk of infection with hepatitis B and C viruses H Hagan, JP McGough, H Thiede, NS Weiss, S Hopkins, ER Alexander American journal of epidemiology 149 (3), 203-213, 1999 | 331 | 1999 |
| Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta‐analysis L Platt, S Minozzi, J Reed, P Vickerman, H Hagan, C French, A Jordan, ... Addiction 113 (3), 545-563, 2018 | 323 | 2018 |
Samuel M. JennessAssociate Professor of Epidemiology, Emory UniversityVerified email at emory.edu
